<DOC>
	<DOCNO>NCT02076295</DOCNO>
	<brief_summary>Mild cognitive impairment dementia frequent non-motor complication moderate advance Parkinson 's disease . Brain positron emission tomography ( PET ) study finding confirm post-mortem evidence cholinergic loss relate cognitive impairment Parkinson 's disease . However , current cholinergic augmentation therapy always effective target Parkinson 's disease patient evidence cholinergic system impairment . The objective study study association particular subtype cholinergic receptor , so-called nicotinic acetylcholine receptor , cognition Parkinson 's disease use novel PET marker cholinergic system integrity .</brief_summary>
	<brief_title>Cholinergic Nicotinic Receptors Cognition PD</brief_title>
	<detailed_description>Parkinson 's disease patient undergo nicotinic acetylcholine receptor PET image radioligand [ 18F ] flubatine MRI one day extensive neuropsychological test another day . The degree nicotinic receptor expression obtain PET image correlated neuropsychology test result . Positive [ 18F ] flubatine PET finding study would establish nicotinic receptor important contributor cognitive dysfunction Parkinson 's disease could kindle pharmaceutical interest pursue agent Parkinson 's disease application . We expect low nicotinic receptor expression associate impaired cognitive function Parkinson 's disease . In personalized medicine approach PET radioligand [ 18F ] flubatine could serve important marker identify patient expect benefit nicotinic receptor drug treatment .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Cholinergic Agents</mesh_term>
	<criteria>Inclusion criterion : PD subject ( M/F , nonsmoking , ≥ 50 year old , Hoehn &amp; Yahr stag 14 ) Normal control subject ( N=15 , M/F , nonsmoking , ≥ 50 year old ) Active smoking , use tobacco product , use nicotinic drug nicotine patch varenicline . Subjects contraindication MR imaging , include pacemaker claustrophobia . Evidence large vessel stroke mass lesion MRI . Use ( anti ) cholinergic neuroleptic drug . Dementia severe cognitive impairment confirm clinical detailed neuropsychological assessment preclude safe study participation , perform study procedure , unable follow direction study personnel . Evidence atypical parkinsonism neurological exam . Subjects limited participation research procedures involve ionize radiation . Pregnancy ( test within 48 hour PET session ) breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cognition</keyword>
	<keyword>Cholinergic nicotinic receptor</keyword>
	<keyword>Positron Emission Tomography</keyword>
</DOC>